908 Devices (NASDAQ:MASS) Given Sell (E+) Rating at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 908 Devices (NASDAQ:MASS - Free Report) in a research note released on Saturday, May 24th,Weiss Ratings reports.

908 Devices Price Performance

NASDAQ MASS traded down $0.09 during mid-day trading on Friday, reaching $5.76. 641,327 shares of the stock were exchanged, compared to its average volume of 1,007,845. 908 Devices has a one year low of $1.81 and a one year high of $6.44. The stock has a 50 day simple moving average of $4.78 and a 200-day simple moving average of $3.40. The stock has a market cap of $206.56 million, a P/E ratio of -3.25 and a beta of 0.26.

908 Devices (NASDAQ:MASS - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%. The business had revenue of $11.78 million during the quarter, compared to the consensus estimate of $11.90 million. Sell-side analysts anticipate that 908 Devices will post -1.99 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Mark Spoto bought 10,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was acquired at an average price of $4.29 per share, with a total value of $42,900.00. Following the completion of the purchase, the director now directly owns 62,971 shares of the company's stock, valued at approximately $270,145.59. This represents a 18.88% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 27.70% of the stock is owned by insiders.

Institutional Investors Weigh In On 908 Devices

A number of large investors have recently bought and sold shares of MASS. Two Sigma Advisers LP acquired a new stake in 908 Devices in the fourth quarter worth $30,000. CWM LLC grew its holdings in 908 Devices by 541.2% in the first quarter. CWM LLC now owns 6,963 shares of the company's stock worth $31,000 after purchasing an additional 5,877 shares during the period. Prudential Financial Inc. acquired a new stake in 908 Devices in the fourth quarter worth $34,000. Occudo Quantitative Strategies LP acquired a new stake in 908 Devices in the fourth quarter worth $36,000. Finally, Two Sigma Investments LP acquired a new stake in 908 Devices in the fourth quarter worth $42,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.